InvestorsHub Logo
Followers 0
Posts 94
Boards Moderated 0
Alias Born 05/10/2012

Re: Tails post# 41785

Monday, 09/16/2013 3:20:06 PM

Monday, September 16, 2013 3:20:06 PM

Post# of 403047
Tails,

There is some risk with Brilacidin. I was a heavy investor in Polymedix and in it at the time management blindsided us with PMX-60056 blood pressure problems. Since the two products are fairly closely related, concerns are valid.

That said, there didn't appear to be any similar problems with Brilacidin P2a, but who knows? In many of our (PYMX investors) minds, management withheld material information regarding PMX-60056 long after they knew of the BP problems. In fact, the announcement of trial discontinuation was the beginning of the end for the company, as well as the trigger for numerous lawsuits.

Many of us wondered how a product (Brilacidin) that had so much potential and displayed supposedly superior efficacy to its competition could not be picked up by a major pharmaceutical. I think a number of us were quite suprised to see a small biotech like Cellceutix buy Polymedix' assets for such a low price rather than a big pharmaceutical. It makes me wonder...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News